A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with no or moderate RBC transfusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenaux, Pierre, Santini, Valeria, Spiriti, Maria Antonietta Aloe, Giagounidis, Aristoteles, Schlag, Rudolf, Radinoff, Atanas, Gercheva-Kyuchukova, Liana, Anagnostopoulos, Achilles, Oliva, Esther Natalie, Symeonidis, Argiris, Berger, Mathilde Hunault, Götze, Katharina S., Potamianou, Anna, Haralampiev, Hari, Wapenaar, Robert, Milionis, Iordanis, Platzbecker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286328/
https://www.ncbi.nlm.nih.gov/pubmed/29895954
http://dx.doi.org/10.1038/s41375-018-0118-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286328/
https://www.ncbi.nlm.nih.gov/pubmed/29895954
http://dx.doi.org/10.1038/s41375-018-0118-9

Ejemplares similares